



Eric A. Hughes, MD, PhD  
Executive Vice President,  
Global Research & Development  
Chief Medical Officer  
Teva Pharmaceuticals

Dr. Eric A. Hughes was appointed Executive Vice President, Global R&D and Chief Medical Officer at Teva in August 2022. He is an accomplished scientist and licensed physician with specialty training in infectious diseases and immunology paired with nearly 20 years of experience in all phases of drug development in leading global pharmaceutical companies.

At Teva, Dr. Hughes oversees a global R&D organization of ~3,700 colleagues responsible for the discovery, development, registration, medical affairs and patient safety activities for one of the biggest and most diverse generics portfolios in the world, one of the broadest early-stage biosimilar pipelines in the industry, and an innovative medicines pipeline anchored in novel biologics.

Prior to Teva, Dr. Hughes was Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals in Boston, Massachusetts, in the US. From 2015 to 2021, he was Global Development Unit Head for Immunology, Hepatology and Dermatology at Novartis in Switzerland, ultimately responsible for leading all clinical development activities and biostatistician talent across multiple therapeutic areas and for expanding development in China.

During the pandemic in 2020 and 2021, Dr. Hughes served as Co-Chair of the Therapeutics Clinical Working Group for The Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership at The National Institutes of Health.

Dr. Hughes launched his career in the pharmaceutical industry in 2004 at Bristol Myers-Squibb Company (BMS) and moved to Schering-Plough Research Institute in 2006. Beginning in 2009, he spent a year at Merck Research Laboratories as the Director of Clinical Research for Hepatology before returning to BMS in 2010 where his career there culminated in 2015 as Head of Virology, Fibrotic Diseases, Genetically Defined Diseases, Autoimmunity, and Cardiology Discovery Medicine, Exploratory Clinical & Translational Research.

Dr. Hughes earned his MD and PhD at Yale School of Medicine. He completed his medical residency with the Department of Internal Medicine at Yale New Haven Hospital/Yale University School of Medicine, and a Fellowship in Infectious Diseases at the Yale University School of Medicine. He is a prolific and widely published scientist, co-authoring more than 30 articles in peer-reviewed scientific journals, and has a deep passion for helping patients.

***Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people's lives for more than a century. We are a global leader in generic, biosimilar and innovative medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of innovative medicines and biopharmaceutical products. Learn more at [www.tevapharm.com](http://www.tevapharm.com).***